Pediatrics

0

Launch of TASECTAN® AF in Finland and Sweden

Following the launch of TASECTAN® AF in Denmark in August, Pharmaforce has just marketed this product also in Finland (September) and Sweden (October). Last April, Noventure granted Pharmaforce exclusive distribution right for TASECTAN® AF in the Nordic markets. TASECTAN® AF is intended to restore the physiological functions of the intestinal walls. It is specifically formulated for the control and reduction of the symptoms related to diarrheal events of different aetiologies in adults and children. TASECTAN® AF is a class IIa medical device and complies with the Essential Requirements of Directive 93/42/EEC and subsequent amendments (CE 0476, Noventure SL). For more information about our products click here: http://noventure.com/products

Read more

“Advantages of Gel Oral Rehydration Solutions (ORS) for the Management of Acute Diarrhea: An Update”

Piqué N, Miñana-Galbis D, Machlab S. Advantages of Gel Oral Rehydration Solutions (ORS) for the Management of Acute Diarrhea: An Update. Ann Pediatr Child Health 2020; 8(6): 1194.

We are proud to announce the publication “Advantages of Gel Oral Rehydration Solutions (ORS) for the Management of Acute Diarrhea: An Update”. This article elaborates on how a friendlier use of ORS is possible by improving palatability and texture, as well as limiting the volume per dosing. As a result, treatment compliance and, subsequently, therapeutic success, are more likely than with standard ORS preparations.

Read more

Let's meet in..

2022, Feb 01

EWMA

Read more

2022, Mar 07

28th International Conference on Clinical Nutrition 2022

Read more

2022, Mar 18

EAU22

Read more